Cargando…
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans
BACKGROUND: Cryptococcal meningitis has fatality rates of 40%‐70%, resulting in 200 000 deaths each year. The best outcomes are achieved with amphotericin combined with flucytosine but flucytosine is expensive and unavailable where most disease occurs. More effective and affordable treatments are ne...
Autores principales: | Hai, Trieu Phan, Van, Anh Duong, Ngan, Nguyen Thi Thuy, Nhat, Le Thanh Hoang, Lan, Nguyen Phu Huong, Vinh Chau, Nguyen V., Thwaites, Guy E., Krysan, Damian, Day, Jeremy N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771715/ https://www.ncbi.nlm.nih.gov/pubmed/31173410 http://dx.doi.org/10.1111/myc.12955 |
Ejemplares similares
-
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2021) -
A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2019) -
Multilocus sequence typing of Cryptococcus neoformans var. grubii from Laos in a regional and global context
por: Thanh, Lam Tuan, et al.
Publicado: (2019) -
Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B
por: Carlson, Tyler, et al.
Publicado: (2021) -
Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole
por: Ghaffar, Muhammad, et al.
Publicado: (2019)